14-day Premium Trial Subscription Try For FreeTry Free
$28.52
+1.08 (+3.94%)
At Close: May 01, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile
Date Action Amount Person Type
Apr 24, 2024 Sell 3 261 Geffner Michael Common Stock
Apr 24, 2024 Sell 7 239 Stout Jay S Common Stock
Apr 24, 2024 Sell 3 963 Levine Mark S. Common Stock
Apr 17, 2024 Sell 7 602 Levine Mark S. Common Stock
Apr 17, 2024 Sell 2 225 Levine Mark S. Common Stock
Apr 17, 2024 Sell 6 136 Macias William L. Common Stock
Apr 17, 2024 Sell 1 796 Macias William L. Common Stock
Apr 17, 2024 Sell 269 Macias William L. Common Stock
Apr 17, 2024 Sell 79 Macias William L. Common Stock
Apr 17, 2024 Sell 9 479 Barnett Eva Renee Common Stock
Apr 17, 2024 Sell 2 774 Barnett Eva Renee Common Stock
Apr 17, 2024 Sell 7 825 Butchko Julia G. Common Stock
Apr 17, 2024 Sell 2 290 Butchko Julia G. Common Stock
Apr 17, 2024 Sell 26 365 Salzmann Peter Common Stock
Apr 17, 2024 Sell 7 714 Salzmann Peter Common Stock
Apr 09, 2024 Sell 3 689 Barnett Eva Renee Common Stock
Apr 09, 2024 Sell 1 053 Butchko Julia G. Common Stock
Apr 09, 2024 Sell 4 807 Salzmann Peter Common Stock
Apr 02, 2024 Buy 11 255 Fromkin Andrew J. Common Stock
Apr 02, 2024 Buy 4 690 Fromkin Andrew J. Stock Option (right to buy)
Apr 02, 2024 Buy 11 255 Hughes Douglas J. Common Stock
Apr 02, 2024 Buy 4 690 Hughes Douglas J. Stock Option (right to buy)
Apr 02, 2024 Buy 11 255 Migausky George V Common Stock
Apr 02, 2024 Buy 4 690 Migausky George V Stock Option (right to buy)
Apr 02, 2024 Buy 11 255 Pande Atul Common Stock
Apr 02, 2024 Buy 4 690 Pande Atul Stock Option (right to buy)
Apr 02, 2024 Buy 120 400 Torti Frank Common Stock
Apr 02, 2024 Buy 50 167 Torti Frank Stock Option (right to buy)
Apr 02, 2024 Buy 54 978 Stout Jay S Common Stock
Apr 02, 2024 Buy 68 723 Stout Jay S Stock Option (right to buy)
Apr 02, 2024 Buy 54 978 Levine Mark S. Common Stock
Apr 02, 2024 Buy 68 723 Levine Mark S. Stock Option (right to buy)
Apr 02, 2024 Buy 54 978 Macias William L. Common Stock
Apr 02, 2024 Buy 68 723 Macias William L. Stock Option (right to buy)
Apr 02, 2024 Buy 54 978 Geffner Michael Common Stock
Apr 02, 2024 Buy 68 723 Geffner Michael Stock Option (right to buy)
Apr 02, 2024 Buy 54 978 Butchko Julia G. Common Stock
Apr 02, 2024 Buy 68 723 Butchko Julia G. Stock Option (right to buy)
Apr 02, 2024 Buy 54 978 Barnett Eva Renee Common Stock
Apr 02, 2024 Buy 68 723 Barnett Eva Renee Stock Option (right to buy)
Apr 02, 2024 Buy 160 534 Salzmann Peter Common Stock
Apr 02, 2024 Buy 200 667 Salzmann Peter Stock Option (right to buy)
Feb 22, 2024 Sell 2 930 Barnett Eva Renee Common Stock
Feb 22, 2024 Sell 2 134 Levine Mark S. Common Stock
Feb 22, 2024 Sell 2 221 Macias William L. Common Stock
Feb 22, 2024 Sell 2 146 Butchko Julia G. Common Stock
Feb 22, 2024 Sell 13 454 Salzmann Peter Common Stock
Jan 26, 2024 Sell 2 981 Levine Mark S. Common Stock
Jan 26, 2024 Sell 46 Levine Mark S. Common Stock
Jan 26, 2024 Sell 9 948 Geffner Michael Common Stock
Jan 26, 2024 Sell 153 Geffner Michael Common Stock
Jan 18, 2024 Sell 424 Macias William L. Common Stock
Jan 17, 2024 Buy 150 000 Geffner Michael Stock Option (right to buy)
Jan 16, 2024 Buy 0 Geffner Michael Common Stock
Jan 11, 2024 Sell 2 681 Barnett Eva Renee Common Stock
Jan 11, 2024 Sell 834 Barnett Eva Renee Common Stock
Jan 05, 2024 Sell 1 297 Butchko Julia G. Common Stock
Jan 05, 2024 Sell 3 824 Salzmann Peter Common Stock
Dec 01, 2023 Sell 3 941 Fromkin Andrew J. Common Stock
Dec 01, 2023 Sell 3 636 Fromkin Andrew J. Common Stock
Dec 01, 2023 Sell 4 773 Fromkin Andrew J. Common Stock
Dec 01, 2023 Sell 4 129 Pande Atul Common Stock
Dec 01, 2023 Sell 3 374 Pande Atul Common Stock
Dec 01, 2023 Sell 4 847 Pande Atul Common Stock
Dec 01, 2023 Sell 4 200 Migausky George V Common Stock
Dec 01, 2023 Sell 3 478 Migausky George V Common Stock
Dec 01, 2023 Sell 5 022 Migausky George V Common Stock
Nov 22, 2023 Sell 15 601 Salzmann Peter Common Stock
Nov 22, 2023 Sell 616 Salzmann Peter Common Stock
Nov 22, 2023 Sell 3 901 Barnett Eva Renee Common Stock
Nov 22, 2023 Sell 154 Barnett Eva Renee Common Stock
Nov 22, 2023 Sell 3 141 Butchko Julia G. Common Stock
Nov 22, 2023 Sell 124 Butchko Julia G. Common Stock
Nov 22, 2023 Sell 3 141 Macias William L. Common Stock
Nov 22, 2023 Sell 124 Macias William L. Common Stock
Nov 22, 2023 Sell 3 128 Levine Mark S. Common Stock
Nov 22, 2023 Sell 124 Levine Mark S. Common Stock
Oct 25, 2023 Sell 4 107 Levine Mark S. Common Stock
Oct 19, 2023 Sell 530 Macias William L. Common Stock
Oct 10, 2023 Sell 4 557 Barnett Eva Renee Common Stock
Oct 05, 2023 Sell 296 Butchko Julia G. Common Stock
Oct 05, 2023 Sell 1 439 Butchko Julia G. Common Stock
Oct 05, 2023 Sell 894 Salzmann Peter Common Stock
Oct 05, 2023 Sell 4 345 Salzmann Peter Common Stock
Oct 02, 2023 Buy 1 526 316 Roivant Sciences Ltd. Common Stock, $0.0001 par value per share
Oct 02, 2023 Buy 4 473 684 Roivant Sciences Ltd. Common Stock, $0.0001 par value per share
Aug 30, 2023 Sell 50 866 Salzmann Peter Common Stock
Aug 30, 2023 Sell 5 908 Salzmann Peter Common Stock
Aug 24, 2023 Sell 12 285 Levine Mark S. Common Stock
Aug 24, 2023 Sell 1 Levine Mark S. Common Stock
Aug 24, 2023 Sell 14 385 Barnett Eva Renee Common Stock
Aug 24, 2023 Sell 1 Barnett Eva Renee Common Stock
Aug 24, 2023 Sell 12 332 Butchko Julia G. Common Stock
Aug 24, 2023 Sell 1 Butchko Julia G. Common Stock
Aug 24, 2023 Sell 12 332 Macias William L. Common Stock
Aug 24, 2023 Sell 1 Macias William L. Common Stock
Aug 14, 2023 Sell 91 744 Salzmann Peter Common Stock
Aug 14, 2023 Sell 11 314 Salzmann Peter Common Stock
Aug 07, 2023 Sell 101 339 Salzmann Peter Common Stock
Jul 26, 2023 Sell 3 917 Levine Mark S. Common Stock
JSON CSV
INSIDER POWER
85.662
Last 100 transactions
Buy: 7 487 754 | Sell: 543 687 (Shares)

Based on the 100 latest insides trades, we have calculated the insider power to be positive at a ratio of 85.662.

In total, the insiders bought 7 487 754 and sold 543 687 IMVT shares in the last 100 trades.

Click to get the best stock tips daily for free!

About Immunovant, Inc.

Immunovant. Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for... IMVT Profile

Golden Star

Ticker Date Change Price
HRB Apr 29 1.00% $47.23
LYG Apr 29 0.391% $2.56
ORA Apr 29 1.95% $64.48
ETSY Apr 26 3.43% $67.43
DHT Apr 24 0.98% $11.28
LPLA Apr 19 1.10% $262.59
MLI Apr 19 7.29% $52.28
PFLT Apr 18 1.33% $11.25
DOOR Apr 18 0.94% $131.39
OCSL Apr 17 0.360% $19.43
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT